DERWENT-ACC-NO: 1999-153313
DERWENT-WEEK: 200063

TITLE: Diagnosis, treatment and prevention of diabetes and other autoimmune
diseases - using antibodies reactive with anti-T-cell receptor Vbeta antibody

INVENTOR: MATOSSIAN-ROGERS, A

PATENT-ASSIGNEE: MATOSSIAN-ROGERS A[MATOI]

PRIORITY-DATA: 1998GB-0010676 (May 18, 1998) , 1997GB-0015281 (July 21, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CN 1264426 A	August 23, 2000	N/A	000	C12N 015/09
WO 9905175 A2	February 4, 1999	E	072	C07K 016/00
AU 9884517 A	February 16, 1999	N/A	000	C07K 016/00
EP 998556 A2	May 10, 2000	E	000	C12N 015/09
BR 9810118 A	August 8, 2000	N/A	000	C07K 016/00

DESIGNATED-STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI G
B GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW
MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AT BE CH
CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW A
L AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI

APPLICATION-DATA:

PUB-NO	APPL-DESCRIPTOR	APPL-NO	APPL-DATE
CN 1264426A	N/A	1998CN-0807380	July 20, 1998
WO 9905175A2	N/A	1998WO-GB02151	July 20, 1998

AU 9884517A July 20, 1998	N/A	1998AU-0084517
AU 9884517A N/A	Based on	WO 9905175
EP 998556A2 July 20, 1998	N/A	1998EP-0935160
EP 998556A2 July 20, 1998	N/A	1998WO-GB02151
EP 998556A2 N/A	Based on	WO 9905175
BR 9810118A July 20, 1998	N/A	1998BR-0010118
BR 9810118A July 20, 1998	N/A	1998WO-GB02151
BR 9810118A N/A	Based on	WO 9905175

INT-CL_(IPC): A61K038/16; A61K039/395 ; C07K014/435 ; C07K016/00 ;
C07K016/42 ; C12N015/09

RELATED-ACC-NO: 1999-073525

ABSTRACTED-PUB-NO: WO 9905175A
BASIC-ABSTRACT: Use as a pharmaceutical or diagnostic reagent of one of the
following is new: (a) mono- or poly-clonal antibodies (Ab1), or equivalent
ligand, reactive with an anti-TCR (T-cell receptor) V beta antibody (Ab2); (b)
(oligo- or poly-)peptide or protein (I), bound to Ab1, or its equivalent
ligand, that is not Ab2; (c) genomic DNA, cDNA or RNA (II) encoding Ab1,
equivalent ligand or (I); (d) bacteriophage clone, plasmid or viral vector
containing (II), designated (IIa), that encodes the ESRP1 protein (endocrine
secretion regulatory protein). Also new are (1) any (I), designated (Ia),
containing the ESRP1 sequence (of 410 amino acids, given in the specification);
(2) any nucleic acid (IIa) encoding ESRP1; (3) bacteriophage clone, plasmid or
viral vector containing (IIa); (4) host cells stably transfected or transformed
with a plasmid or vector of (3).

USE - Ab1, (I) or (Ia) are used to treat or prevent (non-)insulin-dependent
diabetes mellitus, (non-)organ-specific autoimmune diseases,

cardiovascular
diseases, cachexia, cancer and generally any condition associated with
anti-phospholipid (PL) antibodies, hyperinsulinaemia and insulin resistance.
Ab1, and equivalent ligands, are also used to detect and quantify natural
autoantibodies (Ab3) in blood, plasma and serum, for determining susceptibility
to autoimmune disease and for prognosis of disease or treatment efficiency.
The method is based on the idea that Ab3 are responsible for autoimmune
diseases, e.g. in the case of diabetes they bind to proteins on alpha -cells,
resulting in dysregulation of insulin secretion and then beta -cell death.

CHOSEN-DRAWING: Dwg.0/7

TITLE-TERMS:
DIAGNOSE TREAT PREVENT DIABETES DISEASE ANTIBODY REACT ANTI CELL RECEPTOR
ANTIBODY

DERWENT-CLASS: B04 D16 S03

CPI-CODES: B04-B04D4; B04-B04D5; B04-E02; B04-E03; B04-E08; B04-F0100E;
B04-F1100E; B04-G01; B04-G21; B04-G22; B04-H01; B04-N04; B11-C07A; B12-K04A;
B14-E11; B14-F01; B14-F02; B14-G02D; B14-H01; B14-S04; D05-H09; D05-H10;
D05-H11; D05-H12A; D05-H12E; D05-H14; D05-H17A2;

CHEMICAL-CODES:
Chemical Indexing M1 *01*
Fragmentation Code
M423 M710 M903 P433 P520 P522 P631 P633 P816 P831
Q233 V600 V611

Chemical Indexing M1 *02*
Fragmentation Code
M423 M710 M903 P433 P520 P522 P631 P633 P816 Q233
V752 V901 V902

Chemical Indexing M1 *03*
Fragmentation Code
M423 M710 M903 Q233 V753

Chemical Indexing M1 *04*

Fragmentation Code
M423 M710 M903 N135 Q233 V500 V540 V560 V754

SECONDARY-ACC-NO:
CPI Secondary Accession Numbers: C1999-045200

RESULT 1
X22754
ID X22754 standard; DNA; 1231 BP.
XX
AC X22754;
XX
DT 07-JUN-1999 (first entry)
XX
DE Human ESRP1 DNA.
XX
KW ESRP1; treatment; prevention; non-insulin-dependent diabetes mellitus;
KW non-organ-specific autoimmune disease; cardiovascular disease; cancer;
KW cachexia; anti-phospholipid antibody; hyperinsulinaemia; T-cell receptor;
KW insulin resistance; monoclonal; polyclonal; anti-TCR; V beta antibody;
KW detection; autoantibody; blood; plasma; serum; autoimmune disease; human;
KW alpha-cell; dysregulation; insulin secretion; beta-cell death; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..1231
FT /*tag= a
FT /product= "ESRP1"
FT /partial
FT /codon_start= 2
XX
PN WO9905175-A2.
XX
PD 04-FEB-1999.
XX
PF 20-JUL-1998; 98WO-GB02151.
XX
PR 18-MAY-1998; 98GB-0010676.
PR 21-JUL-1997; 97GB-0015281.
XX
PA (MATO/) MATOSSIAN-ROGERS A.
XX
PI Matossian-Rogers A;
XX
DR WPI; 1999-153313/13.
DR P-PSDB; W93254.
XX
PT Diagnosis, treatment and prevention of diabetes and other autoimmune
PT diseases - using antibodies reactive with anti-T-cell receptor Vbeta
PT antibody
XX
PS Disclosure; Fig 6; 72pp; English.
XX
CC This sequence encodes the human ESRP1 protein. This protein or
CC antibody fragments generated from it are used to treat or prevent
CC (non-)insulin-dependent diabetes mellitus, (non-)organ-specific
CC autoimmune diseases, cardiovascular diseases, cachexia, cancer and
CC generally any condition associated with anti-phospholipid antibodies,
CC hyperinsulinaemia and insulin resistance. Mono- or poly-clonal antibodies
CC and equivalent ligands reactive with an anti-TCR (T-cell receptor) V beta
CC antibody are also used to detect and quantify natural autoantibodies in
CC blood, plasma and serum, for determining susceptibility to autoimmune

CC disease and for prognosis of disease or treatment efficiency. The method
CC is based on the idea that autoantibodies are responsible for autoimmune
CC diseases, e.g. in the case of diabetes they bind to proteins on
CC alpha-cells, resulting in dysregulation of insulin secretion and then
CC beta-cell death.
XX
SQ Sequence 1231 BP; 287 A; 388 C; 362 G; 194 T; 0 other;

Query Match 41.2%; Score 1088.8; DB 20; Length 1231;
Best Local Similarity 94.9%; Pred. No. 1.4e-224;
Matches 1198; Conservative 0; Mismatches 12; Indels 52; Gaps 5;

```
Qy   1359 ggatgaacagggccccatccgctgcaacaccacagtctgcctgggcaaaatcggctccta 1418
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     10 ggatgaacagggccccatccgctgcaacaccacagtctgcctgggcaaaatcggctccta 69

Qy   1419 cctcagtgctagcaccagacacagggtccttacctctgccttcagccgagccactaggga 1478
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     70 cctcagtgctagcaccagacacagggtccttacctctgccttcagccgagccactaggga 129

Qy   1479 cccgtttgcaccgtcccgggttgcgggtgtcctgggctttgctgccacccacaacctcta 1538
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    130 cccgtttgcaccgtcccgggttgcgggtgtcctgggctttgctgccacccacaacctcta 189

Qy   1539 ctcaatgaacgactgtgcccagaagatcctgcctgtgctctgcggtctcactgtagatcc 1598
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    190 ctcaatgaacgactgtgcccagaagatcctgcctgtgctctgcggtctcactgtagatcc 249

Qy   1599 tgagaaatccgtgcgagaccaggccttcaaggcatttcggagcttcctgtccaaattgga 1658
          |||||||||||||||||||||||||||||||  ||||||||||||||||||||||||||
Db    250 tgagaaatccgtgcgagaccaggccttcaaggccattcggagcttcctgtccaaattgga 309

Qy   1659 gtctgtgtcggaggacccgacccagctggaggaagtggagaaggatgtccatgcagcctc 1718
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    310 gtctgtgtcggaggacccgacccagctggaggaagtggagaaggatgtccatgcagcctc 369

Qy   1719 cagccctggcatgggaggagccgcagctagctgggcaggctgggccgtgaccggggtctc 1778
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    370 cagccctggcatgggaggagccgcagctagctgggcaggctgggccgtgaccggggtctc 429

Qy   1779 ctcactcacctccaagctgatccgttcgcacccaaccactgccccaacagaaaccaacat 1838
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    430 ctcactcacctccaagctgatccgttcgcacccaaccactgccccaacagaaaccaacat 489

Qy   1839 tccccaaagacccacgcctgaaggagttcctgccccagcccccacccctgttcctgccac 1898
          ||||||||||||||||||||  ||||||||||||||||||||||||||||||||||||
Db    490 tccccaaagacccacgcctga---agttcctgccccagcccccacccctgttcctgccac 546

Qy   1899 ccctacaacctcaggccactgggagacgcaggaggaggacaaggacacagcagaggacag 1958
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    547 ccctacaacctcaggccactgggagacgcaggaggaggacaaggacacagcagaagacag 606

Qy   1959 cagcactgctgacagatgggacgacgaagactggggcagcctggagcaggaggccgagtc 2018
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    607 cagcactgctgacagatgggacgacgaagactggggcagcctggagcaggaggccgagtc 666
```


Qy 2019 tgtgctggcccagcaggacgactggagcaccgggggccaagtgagccgtgctagtcaggt 2078
Db 667 tgtgctggcccagcaggacgactggagcaccgggggccaagtgagccgtgctagtcaggt 726
Qy 2079 cagcaactccgaccacaaatcctccaaatccccagagtccgac-tggagcagctgggaag 2137
Db 727 cagcaactccgaccacaaatcctccaaatccccagagtccgacttggagcaactgggaag 786
Qy 2138 ctgagggctcctgggaacagggctggcaggagccaagctcccaggagccaccttctgacg 2197
Db 787 cttaagggtccttgga---------- 802
Qy 2198 gtacacggctggccagcgagtataactggggtggcccagagtccagcgacaagggcgacc 2257
Db 803 --acacggctggccagcgagtataactggggttgcccagagtccagcgacaagggcgacc 860
Qy 2258 ccttcgctaccctgtctgcacgtcccagcacccagccgaggccagactcttggggtgagg 2317
Db 861 ccttcgctaccctgtctgcacgttccagcacccagccgaggccagactcttggggtgagg 920
Qy 2318 acaactgggagggcctcgagactgacagtcgacaggtcaaggctgagctggcccggaaga 2377
Db 921 acaactgggagggcctcgagactgacagtcgacaggtcaaggctgagctggcccggaaga 980
Qy 2378 agcgcgaggagcggcggcgggagatggaggccaaacgcgccgagaggaaggtggccaagg 2437
Db 981 agcgcgaggagcggcggcgggagatggaggccaaacgcgccgagaggaaggtggccaagg 1040
Qy 2438 gccccatgaagctgggagcccggaagctggactgaaccgtggcggtggcccttcccggct 2497
Db 1041 gccccatgaagctgggagcccggaagctgga-tgaaccgtggcggtggcccttcccggct 1099
Qy 2498 gcggagagcccgccccacagatgtatttattgtacaaaccatgtgagcccggccggccca 2557
Db 1100 gcggagagcccgccccacagatgtatttattgtacaaaccatgtgaggccggccggccca 1159
Qy 2558 gccaggccatctcacgtgtacataatcagagccacaataaattctatttcacaaaaaaaa 2617
Db 1160 gccaggccat-tcacgtgtacataatcagagccacaataaatttttatttcacaaaaaaaa 1218
Qy 2618 aa 2619
Db 1219 aa 1220